Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals

Vaccine. 2023 Oct 6;41(42):6146-6149. doi: 10.1016/j.vaccine.2023.08.086. Epub 2023 Sep 9.

Abstract

In a phase 2 safety and immunogenicity study of a chikungunya virus virus-like particle (CHIKV VLP) vaccine in an endemic region, of 400 total participants, 78 were found to be focus reduction neutralizing antibody seropositive at vaccination despite being ELISA seronegative at screening, of which 39 received vaccine. This post hoc analysis compared safety and immunogenicity of CHIKV VLP vaccine in seropositive (n = 39) versus seronegative (n = 155) vaccine recipients for 72 weeks post-vaccination. There were no differences in solicited adverse events, except injection site swelling in 10.3% of seropositive versus 0.6% of seronegative recipients (p = 0.006). Baseline seropositive vaccine recipients had stronger post-vaccination luciferase neutralizing antibody responses versus seronegative recipients (peak geometric mean titer of 3594 and 1728, respectively) persisting for 72 weeks, with geometric mean fold increases of 3.1 and 13.2, respectively. In this small study, CHIKV VLP vaccine was well-tolerated and immunogenic in individuals with pre-existing immunity. ClinicalTrials.gov Identifier: NCT02562482.

Keywords: Chikungunya virus; Immunogenicity; Safety; Seropositive; VLP vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Chikungunya Fever* / prevention & control
  • Chikungunya virus*
  • Double-Blind Method
  • Humans
  • Immunogenicity, Vaccine
  • Vaccines, Virus-Like Particle*
  • Viral Vaccines*

Substances

  • Vaccines, Virus-Like Particle
  • Viral Vaccines
  • Antibodies, Viral
  • Antibodies, Neutralizing

Associated data

  • ClinicalTrials.gov/NCT02562482